Clinical course of psoriasis patients that discontinued biologics during the COVID‐19 pandemic
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Cosmetic Dermatology"
DOI: 10.1111/jocd.15638
Abstract: Since psoriasis is a chronic disease, it is not recommended to discontinue the treatment agents used. However, in real life, the treatment of psoriasis patients may be interrupted for various reasons. During the pandemic period,… read more here.
Keywords: patients discontinued; clinical course; psoriasis patients; psoriasis ... See more keywords
SAT0444 Incidence and predictors of immunosuppressant discontinuation and risk of subsequent flare in patients with systemic lupus erythematosus
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.6299
Abstract: Background Prolonged treatment with immunosuppressants (IS) has been associated with long-term complications in Systemic Lupus Erythematosus (SLE); however, few data on IS discontinuation in remitted patients are available to date. Objectives We conducted an observational… read more here.
Keywords: risk; remission; patients discontinued; subsequent flare ... See more keywords
Characteristics of colorectal patients who discontinued oxaliplatin therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e15155
Abstract: e15155 Background: The 3rd generation platinum-based drug, Oxaliplatin, is indicated for treatment of stage II-IV colorectal cancer (CRC). Oxaliplatin combination with Fluorouracil and Leucovorin (FOLFOX) yields a 5-year disease free survival rate of 78%. Oxaliplatin… read more here.
Keywords: therapy; discontinued oxaliplatin; lower among; significantly lower ... See more keywords
Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS working party.
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18258
Abstract: It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who… read more here.
Keywords: hematology; treatment; lower risk; patients discontinued ... See more keywords